Expiratory and Plasma Propofol Concentration in Gastrological Surgery Patients
1 other identifier
interventional
30
1 country
1
Brief Summary
Determination of accuracy With Edmond (reg) expiratory propofol measurement Device, compared With concommitant plasma samples of propofol
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2018
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 14, 2018
CompletedFirst Submitted
Initial submission to the registry
January 18, 2019
CompletedFirst Posted
Study publicly available on registry
January 25, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2020
CompletedFebruary 5, 2019
February 1, 2019
8 months
January 18, 2019
February 2, 2019
Conditions
Outcome Measures
Primary Outcomes (2)
exhaled propofol concentration
parts per billion
start of anaesthesia to end of anaesthesia, 2-3 hours in total
propofol plasma concentration
microg pr ml
4-6 samples in the period between start and end of anaesthesia
Secondary Outcomes (5)
calculated plasma concentration
From start of anaesthesia until end of anaesthesia, 1-3 hrs in total
BIS
from start of anaesthesia until end of anaestheisa, 1-3 hours in total
calculated effect site concentration
from start of anaesthesia until end of anaesthesia, 1-3 hours in total
EEG Power spectrum
f
EEG Power distribution
from start of anaesthesia until end of anaesthesia, 1-3 hours in total
Study Arms (2)
Bariatric surgery
EXPERIMENTALPatients due for bariatric surgery, BMI \> 30
Cholecystectomy
EXPERIMENTALNormal weight patients due for cholecystectomies
Interventions
exhaled propofol will be compared With plasma propofol values
Eligibility Criteria
You may qualify if:
- Patients admitted to Oslo University Hospital, scheduled for elective laparoscopic bariatric surgery or elective laparoscopic cholecystectomy.
- Both genders.
- Age 18-60 years, both inclusive.
- BMI ≥ 20 kg/m2, 10 patients with BMI 20-30, and 10 patients with BMI \> 40
- ASA classification I-III
You may not qualify if:
- Known hypersensitivity or other contraindication to propofol administered as Target Controlled Infusion.
- Patients which during a preoperative visit are deemed not to tolerate propofol bolus or infusion as administered by Target Controlled Infusion.
- Ongoing neuroleptic medication.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Dept of Anesthesiology, Oslo University Hospital, Ullevaal
Oslo, 0407, Norway
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
January 18, 2019
First Posted
January 25, 2019
Study Start
November 14, 2018
Primary Completion
June 30, 2019
Study Completion
December 31, 2020
Last Updated
February 5, 2019
Record last verified: 2019-02